8-K: Vivani Medical to Present at Key Industry Events, Highlighting Long-Acting Drug Delivery Technology

Vivani Medical will present its innovative drug implant technology at the Partnership Opportunities in Drug Delivery (PODD) Event and the ThinkEquity Conference in October 2024.

Summary

• Vivani Medical, a biopharmaceutical company, is scheduled to present at two industry events in October 2024.
• The company will participate in a panel discussion at the Partnership Opportunities in Drug Delivery (PODD) Event in Boston on October 29, 2024.
• Vivani's CEO, Dr. Adam Mendelsohn, will present a company update at the ThinkEquity Conference in New York on October 30, 2024.
• A webcast of the ThinkEquity Conference presentation will be available on Vivani's website.
• Vivani is developing long-acting drug implants using its NanoPortal platform.
• Their lead program, NPM-115, is a six-month subdermal exenatide implant for chronic weight management.
• The company is also developing NPM-139, a semaglutide implant with potential for once-yearly administration, also for weight management.
• NPM-119 is a six-month exenatide implant for Type 2 Diabetes.
• Vivani aims to address medication non-adherence, which affects approximately 50% of patients and contributes to significant healthcare costs and preventable deaths.
• The company believes its long-acting implants offer a differentiated approach in the GLP-1 market.

Sentiment

Score: 7

Explanation: The document is positive due to the upcoming presentations and the potential of the company's technology, but it also acknowledges the risks associated with drug development and the company's financial situation.

Positives

• Vivani's long-acting implant technology has the potential to improve patient adherence to medication.
• The company's focus on GLP-1 implants for weight management and diabetes addresses significant market needs.
• The potential for once-yearly administration with the NPM-139 semaglutide implant is a significant advantage.
• The company is actively engaging with the investment community through presentations at industry events.

Negatives

• The document highlights the risks associated with the development and commercialization of Vivani's products.
• The company has a history of losses and may need to access additional capital to fund its business.

Risks

• There are risks related to the development and commercialization of Vivani's products, including NPM-115 and NPM-119.
• Delays and changes in the development of Vivani's products could occur due to applicable laws, regulations, and guidelines.
• There are potential delays in submitting and receiving regulatory clearance or approval to conduct development activities.
• Risks are associated with the initiation, enrollment, and conduct of planned clinical trials and the results therefrom.
• The company has a history of losses and may face challenges in accessing additional capital.

Future Outlook

The company is focused on advancing its pipeline of long-acting drug implants and plans to present at upcoming industry events to highlight its technology and development programs. The company is also planning the initiation of the LIBERATE-1 trial.

Management Comments

• Dr. Adam Mendelsohn, Vivani's CEO, will provide a company update at the ThinkEquity Conference.
• Vivani remains confident that its highly differentiated portfolio of miniature long-acting GLP-1 implants have the potential to provide an attractive therapeutic option for patients, prescribers and payers.

Industry Context

Vivani's focus on long-acting drug delivery aligns with the industry trend towards improving patient adherence and reducing the burden of chronic disease management. The GLP-1 market is competitive, but Vivani's implant technology offers a differentiated approach compared to daily or weekly injectables.

Comparison to Industry Standards

• The GLP-1 market is dominated by companies like Novo Nordisk (Ozempic, Wegovy) and Eli Lilly (Mounjaro, Zepbound) who offer injectable solutions.
• Vivani's approach with long-acting implants is similar to companies like Intarcia Therapeutics (though they have faced challenges) who are developing implantable drug delivery systems.
• The potential for once-yearly administration with Vivani's semaglutide implant would be a significant advantage over current weekly or daily injectable GLP-1 therapies.
• The company's focus on addressing medication non-adherence is a key differentiator in the market.

Stakeholder Impact

• Shareholders may be interested in the company's progress and future plans.
• Employees may be motivated by the company's participation in industry events.
• Patients may benefit from the development of long-acting drug implants.
• Potential partners may be interested in Vivani's technology.

Next Steps

• Vivani will present at the Partnership Opportunities in Drug Delivery (PODD) Event on October 29, 2024.
• Vivani will present at the ThinkEquity Conference on October 30, 2024.
• The company plans to initiate the LIBERATE-1 trial.

Key Dates

Keywords

drug delivery, long-acting implants, GLP-1, exenatide, semaglutide, weight management, diabetes, biopharmaceutical, NanoPortal, medication adherence